Veradermics (MANE) Retained Earnings (2024 - 2026)
Veradermics' (MANE) quarterly Retained Earnings came in at -$150.7 million in Q1 2026, down 22.1% on a QoQ basis from -$123.4 million in Q4 2025.
Analysis
Veradermics (MANE) Retained Earnings (2024 - 2026) Analysis & Trends
Veradermics (MANE) has 2 years of Retained Earnings data on file, last reported at -$150.7 million in Q1 2026.
- Quarterly Retained Earnings changed N/A year-over-year to -$150.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$150.7 million (changed N/A YoY) and the FY2025 annual result came in at -$123.4 million, changed N/A from the prior year.
- Retained Earnings fell to -$150.7 million in Q1 2026, from -$123.4 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of -$123.4 million in Q4 2025 to a low of -$150.7 million in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.10 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -4.00 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.05 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -6.33 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 4.38 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Veradermics | 3.96 Bn | 3.96 Bn | - | 989.26 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 989.26 Mn |
| Mar 31, 2026 | 543.04 Mn |
| Dec 31, 2025 | -123.42 Mn |
| Dec 31, 2024 | -49.23 Mn |